MedKoo Cat#: 574068 | Name: LDV
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

LDV is an α4β1 integrin (VLA-4) ligand and non-fluorescent derivative of LDV FITC.

Chemical Structure

LDV
LDV
CAS#1155866-55-9

Theoretical Analysis

MedKoo Cat#: 574068

Name: LDV

CAS#: 1155866-55-9

Chemical Formula: C48H70N10O12

Exact Mass: 978.5175

Molecular Weight: 979.15

Elemental Analysis: C, 58.88; H, 7.21; N, 14.31; O, 19.61

Price and Availability

Size Price Availability Quantity
1mg USD 450.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
LDV
IUPAC/Chemical Name
(2-(4-(3-(o-tolyl)ureido)phenyl)acetyl)-L-leucyl-L-aspartyl-L-valyl-L-prolyl-L-alanyl-L-alanyl-L-lysine
InChi Key
FQYZPSNPTJYQKB-CGTMUHGOSA-N
InChi Code
InChI=1S/C48H70N10O12/c1-26(2)23-35(53-38(59)24-31-17-19-32(20-18-31)52-48(70)56-33-14-9-8-13-28(33)5)43(64)55-36(25-39(60)61)44(65)57-40(27(3)4)46(67)58-22-12-16-37(58)45(66)51-29(6)41(62)50-30(7)42(63)54-34(47(68)69)15-10-11-21-49/h8-9,13-14,17-20,26-27,29-30,34-37,40H,10-12,15-16,21-25,49H2,1-7H3,(H,50,62)(H,51,66)(H,53,59)(H,54,63)(H,55,64)(H,57,65)(H,60,61)(H,68,69)(H2,52,56,70)/t29-,30-,34-,35-,36-,37-,40-/m0/s1
SMILES Code
CC(C)C[C@@H](C(N[C@H](C(N[C@H](C(N1CCC[C@H]1C(N[C@H](C(N[C@H](C(N[C@H](C(O)=O)CCCCN)=O)C)=O)C)=O)=O)C(C)C)=O)CC(O)=O)=O)NC(CC(C=C2)=CC=C2NC(NC3=C(C)C=CC=C3)=O)=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Product Data
Biological target:
LDV is a α4β1 integrin (VLA-4) ligand, and binds α4β1 integrin in leukemia cells.
In vitro activity:
The tripeptide Leu-Asp-Val (LDV) is known to bind α(4)β(1) integrin in leukemia cells. Here this study has synthesized a LDV peptidomimetic equipped with a biotin-conjugated spacer-arm. Such biotin-conjugated LDV peptidomimetic may thus represent a novel tool for biotechnological applications using avidin interaction for leukapheresis or leukemia cell targeting. Reference: Bioorg Med Chem Lett. 2012 Jan 1;22(1):586-90. https://pubmed.ncbi.nlm.nih.gov/22101134/
In vivo activity:
Furthermore, YK3-LDV coating accelerated the in vivo formation of neointima-like tissue in a rat model with an ePTFE patch implanted into the carotid artery. Reference: Colloids Surf B Biointerfaces. 2022 Aug;216:112576. https://pubmed.ncbi.nlm.nih.gov/35636324/
Solvent mg/mL mM
Solubility
0.01M PBS (pH 7.4) 1.0 1.02
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 979.15 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Gérard E, Meulle A, Feron O, Marchand-Brynaert J. LDV peptidomimetics equipped with biotinylated spacer-arms: synthesis and biological evaluation on CCRF-CEM cell line. Bioorg Med Chem Lett. 2012 Jan 1;22(1):586-90. doi: 10.1016/j.bmcl.2011.10.078. Epub 2011 Oct 31. PMID: 22101134. 2. Njus BH, Chigaev A, Waller A, Wlodek D, Ostopovici-Halip L, Ursu O, Wang W, Oprea TI, Bologa CG, Sklar LA. Conformational mAb as a tool for integrin ligand discovery. Assay Drug Dev Technol. 2009 Oct;7(5):507-15. doi: 10.1089/adt.2009.0203. PMID: 19754304; PMCID: PMC3096548. 3. Kakinoki S, Nishioka S, Arichi Y, Yamaoka T. Stable and direct coating of fibronectin-derived Leu-Asp-Val peptide on ePTFE using one-pot tyrosine oxidation for endothelial cell adhesion. Colloids Surf B Biointerfaces. 2022 Aug;216:112576. doi: 10.1016/j.colsurfb.2022.112576. Epub 2022 May 24. PMID: 35636324. 4. De Marco R, Mazzotti G, Dattoli SD, Baiula M, Spampinato S, Greco A, Gentilucci L. 5-aminomethyloxazolidine-2,4-dione hybrid α/β-dipeptide scaffolds as inductors of constrained conformations: Applications to the synthesis of integrin antagonists. Biopolymers. 2015 Sep;104(5):636-49. doi: 10.1002/bip.22704. PMID: 26211418.
In vitro protocol:
1. Gérard E, Meulle A, Feron O, Marchand-Brynaert J. LDV peptidomimetics equipped with biotinylated spacer-arms: synthesis and biological evaluation on CCRF-CEM cell line. Bioorg Med Chem Lett. 2012 Jan 1;22(1):586-90. doi: 10.1016/j.bmcl.2011.10.078. Epub 2011 Oct 31. PMID: 22101134. 2. Njus BH, Chigaev A, Waller A, Wlodek D, Ostopovici-Halip L, Ursu O, Wang W, Oprea TI, Bologa CG, Sklar LA. Conformational mAb as a tool for integrin ligand discovery. Assay Drug Dev Technol. 2009 Oct;7(5):507-15. doi: 10.1089/adt.2009.0203. PMID: 19754304; PMCID: PMC3096548.
In vivo protocol:
1. Kakinoki S, Nishioka S, Arichi Y, Yamaoka T. Stable and direct coating of fibronectin-derived Leu-Asp-Val peptide on ePTFE using one-pot tyrosine oxidation for endothelial cell adhesion. Colloids Surf B Biointerfaces. 2022 Aug;216:112576. doi: 10.1016/j.colsurfb.2022.112576. Epub 2022 May 24. PMID: 35636324. 2. De Marco R, Mazzotti G, Dattoli SD, Baiula M, Spampinato S, Greco A, Gentilucci L. 5-aminomethyloxazolidine-2,4-dione hybrid α/β-dipeptide scaffolds as inductors of constrained conformations: Applications to the synthesis of integrin antagonists. Biopolymers. 2015 Sep;104(5):636-49. doi: 10.1002/bip.22704. PMID: 26211418.
Chigaev et al (2009) Real-time analysis of conformation-sensitive antibody binding provides new insights into integrin conformational regulation. J.Biol.Chem. 284 14337 PMID: 19251697